Angelini Group - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
40 Pages - GMD12076


Global Markets Direct’s, ‘Angelini Group - Product Pipeline Review - 2014’, provides an overview of the Angelini Group’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Angelini Group’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Angelini Group including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Angelini Group’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Angelini Group’s pipeline products

Reasons to buy

- Evaluate Angelini Group’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Angelini Group in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Angelini Group’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Angelini Group and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angelini Group
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Angelini Group and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Angelini Group Snapshot 5
Angelini Group Overview 5
Key Information 5
Key Facts 5
Angelini Group - Research and Development Overview 6
Key Therapeutic Areas 6
Angelini Group - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Angelini Group - Pipeline Products Glance 13
Angelini Group - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Angelini Group - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Angelini Group - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Angelini Group - Drug Profiles 18
trazodone hydrochloride 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
prulifloxacin 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
bindarit 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecules to Inhibit GSK-3 Beta for CNS and Inflammatory Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AF-3442 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecules to Inhibit Gyrase and Topoisomerase IV for Infectious Diseases 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecules to Inhibit MCPs for Cancer, Pain and Gastroenterological Disorders 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecules to Inhibit mPGES-1 for Cancer, Pain and Inflammation 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Angelini Group - Pipeline Analysis 28
Angelini Group - Pipeline Products by Target 28
Angelini Group - Pipeline Products by Route of Administration 30
Angelini Group - Pipeline Products by Molecule Type 31
Angelini Group - Pipeline Products by Mechanism of Action 32
Angelini Group - Recent Pipeline Updates 34
Angelini Group - Dormant Projects 35
Angelini Group - Company Statement 36
Angelini Group - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Angelini Group, Key Information 5
Angelini Group, Key Facts 5
Angelini Group - Pipeline by Indication, 2014 8
Angelini Group - Pipeline by Stage of Development, 2014 9
Angelini Group - Monotherapy Products in Pipeline, 2014 10
Angelini Group - Partnered Products in Pipeline, 2014 11
Angelini Group - Partnered Products/ Combination Treatment Modalities, 2014 12
Angelini Group - Pre-Registration, 2014 13
Angelini Group - Phase III, 2014 14
Angelini Group - Phase II, 2014 15
Angelini Group - Preclinical, 2014 16
Angelini Group - Discovery, 2014 17
Angelini Group - Pipeline by Target, 2014 29
Angelini Group - Pipeline by Route of Administration, 2014 30
Angelini Group - Pipeline by Molecule Type, 2014 31
Angelini Group - Pipeline Products by Mechanism of Action, 2014 33
Angelini Group - Recent Pipeline Updates, 2014 34
Angelini Group - Dormant Developmental Projects,2014 35
Angelini Group, Subsidiaries 37

List of Figures
Angelini Group - Pipeline by Top 10 Indication, 2014 7
Angelini Group - Pipeline by Stage of Development, 2014 9
Angelini Group - Monotherapy Products in Pipeline, 2014 10
Angelini Group - Partnered Products in Pipeline, 2014 11
Angelini Group - Pipeline by Top 10 Target, 2014 28
Angelini Group - Pipeline by Top 10 Route of Administration, 2014 30
Angelini Group - Pipeline by Top 10 Molecule Type, 2014 31
Angelini Group - Pipeline Products by Top 10 Mechanism of Action, 2014 32


Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

[email protected]
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

[email protected]
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838
+1 212 564 8133 fax